Head and Neck Cancer Drugs Market To Reach $2.58 Billion By 2029 says Visiongain report

20 December 2019
Pharma

Visiongain’s new report the Head and Neck Cancer Drugs Market Report 2019-2029: Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug stores & retail pharmacies), plus analysis of leading companies operating in the global head and neck cancer drugs market.

Increasing global geriatric population, growing prevalence of neck and head cancer, and increasing tobacco and alcohol consumption is expected to increase global head and neck cancer drugs market over the projected period. In 2019, the global head and neck cancer drugs market was valued at $963 million and is expected to reach $2.58 billion by 2029 at a CAGR of 10.3% over the projected period.

According to the World Health Organization, tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Tobacco consumption is ranked as the leading cause of illness, death, and impoverishment. Increasing tobacco consumption has increased the prevalence of head and neck cancer over the past few years and the trend is expected to continue over the course of time. 

Increasing geriatric population in developed as well as developing economies are expected to prone more towards chronic diseases, which in turn is expected to drive the head and neck cancer drugs market. Some identified disruptive drugs are Opdivo, Keytruda, Imfinzi, Bavencio, Yervoy, Tremelimumab, Buparlisib, and Epacadostat.

List of head and neck cancer drugs providers identified in this report are  Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever